- Open
- 1.49
- High
- 1.50
- Low
- 1.23
- Close
- 1.50
- Change
- -0.14 (-10.29%)
- Volume
- 115,427
| 16 Sept 2026 | 07:01:01 | Appointment of Non-Executive Director |
| 16 Sept 2026 | 07:00:02 | Interim Results H1 2026 |
| 15 Sept 2026 | 09:24:24 | Further GCLP Chemoproteomics contract secured |
| 22 Jun 2026 | 07:00:08 | Target engagement/chemoproteomics contract |
| 27 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 21 May 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 23 May 2024 | Annual Report and Accounts (to 2023-12-31) |
Proteome Sciences PLC specializes in protein biomarker research and development, offering contract research services primarily for pharmaceutical and biotechnology companies. The company employs proprietary mass spectrometry-based techniques to detect and characterize proteins in biological samples for diagnostic, prognostic, and therapeutic applications. It also manufactures and licenses TMT® and TMTpro™ reagents for multiplex quantitative proteomics. Proteome Sciences operates in various sectors, including academic research, and is focused on expanding its service offerings, including chemoproteomics and single-cell proteomics, across global markets.
| 16 Sept 2026 | 07:01:01 | Appointment of Non-Executive Director |
| 16 Sept 2026 | 07:00:02 | Interim Results H1 2026 |
| 15 Sept 2026 | 09:24:24 | Further GCLP Chemoproteomics contract secured |
| 22 Jun 2026 | 07:00:08 | Target engagement/chemoproteomics contract |
| 27 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 21 May 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 23 May 2024 | Annual Report and Accounts (to 2023-12-31) |
Proteome Sciences PLC specializes in protein biomarker research and development, offering contract research services primarily for pharmaceutical and biotechnology companies. The company employs proprietary mass spectrometry-based techniques to detect and characterize proteins in biological samples for diagnostic, prognostic, and therapeutic applications. It also manufactures and licenses TMT® and TMTpro™ reagents for multiplex quantitative proteomics. Proteome Sciences operates in various sectors, including academic research, and is focused on expanding its service offerings, including chemoproteomics and single-cell proteomics, across global markets.
| 1 Jun 2026 | 07:00:09 | Directorate Changes |
| 22 Jun 2026 |
| AIM movers: Kazera Global agrees settlement and another disappointment from eEnergy |
| 1 Jun 2026 | AIM movers: Bumper May for RentGuarantor and waiver extension for Litigation Capital Management |
| 12 May 2026 | AIM Market Roundup: Bradda Head, Proservice Building, Tialis |
| 11 May 2026 | AIM Market Roundup: Novacyt, Proteome, Nativo |
| 1 Feb 2026 | AIM weekly movers: Empyrean Energy settles Duyung PSC dispute |
| 26 Jan 2026 | AIM movers: Positive news for Thor Explorations from Senegal and Nativo Resources appoints mining contractor |
| 1 Jun 2026 | 07:00:09 | Directorate Changes |
| 22 Jun 2026 |
| AIM movers: Kazera Global agrees settlement and another disappointment from eEnergy |
| 1 Jun 2026 | AIM movers: Bumper May for RentGuarantor and waiver extension for Litigation Capital Management |
| 12 May 2026 | AIM Market Roundup: Bradda Head, Proservice Building, Tialis |
| 11 May 2026 | AIM Market Roundup: Novacyt, Proteome, Nativo |
| 1 Feb 2026 | AIM weekly movers: Empyrean Energy settles Duyung PSC dispute |
| 26 Jan 2026 | AIM movers: Positive news for Thor Explorations from Senegal and Nativo Resources appoints mining contractor |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £171m | +0.3% | |
| £13m | -0.3% | |
| £11m | +0.0% | |
| £6m | -0.7% | |
| £6m | -0.4% | |
PRMProteome Sciences PLC | £5m | -0.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £171m | +0.3% | |
| £13m | -0.3% | |
| £11m | +0.0% | |
| £6m | -0.7% | |
| £6m | -0.4% | |
PRMProteome Sciences PLC | £5m | -0.3% |
